REGN earnings call for the period ending March 31, 2021.
News & Analysis: Regeneron Pharmaceuticals
The big biotech delivered impressive revenue and earnings growth.
A new delivery method for its COVID-19 treatment may offer a boost.
The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.
Their growth prospects are too good to ignore.
There are a couple of obstacles that could get in the way.
There aren't many deals out there right now, but these are two of the better ones you can snag.
Future growth will depend on its new checkpoint inhibitor wrangling market share away from Merck's Keytruda.
These under-appreciated pharma stocks have the potential to become long-term winners.
This latest pick has been sluggish so far -- but the long-term opportunity may be huge.